Ardelyx Inc
Company Profile
Business description
Ardelyx Inc is a biopharmaceutical company developing and commercialize, first-in-class medicines that meet unmet medical needs. It has developed a platform that enabled the discovery of new biological mechanisms and pathways to develop potent and efficacious therapies that minimize the side effects and drug-drug interactions frequently encountered with traditional, systemically absorbed medicines. It product Tenapanor, branded as IBSRELA, is used for the treatment of adults with IBS-C. Tenapanor, branded as XPHOZAH, is used to reduce serum phosphorus in adults with CKD on dialysis as add-on therapy in patients who have an inadequate response to phosphate binders or who are intolerant of any dose of phosphate binder therapy.
Contact
400 Fifth Avenue
Suite 210
WalthamMA02451
USAT: +1 510 745-1700
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
395
Stocks News & Analysis
stocks
Chart of the Week: We see opportunity in Mineral Resources despite debt concerns
stocks
The ultimate investing hack: dividend growth stocks
stocks
Is the data centre party over for Goodman?
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,906.70 | 9.80 | -0.11% |
| CAC 40 | 8,125.21 | 37.79 | 0.47% |
| DAX 40 | 23,912.84 | 219.13 | 0.92% |
| Dow JONES (US) | 47,882.90 | 408.44 | 0.86% |
| FTSE 100 | 9,707.34 | 15.27 | 0.16% |
| HKSE | 25,935.90 | 175.17 | 0.68% |
| NASDAQ | 23,454.09 | 40.42 | 0.17% |
| Nikkei 225 | 51,028.42 | 1,163.74 | 2.33% |
| NZX 50 Index | 13,515.62 | 66.92 | -0.49% |
| S&P 500 | 6,849.72 | 20.35 | 0.30% |
| S&P/ASX 200 | 8,618.40 | 0.40 | -0.00% |
| SSE Composite Index | 3,875.79 | 2.21 | -0.06% |